A. Bossios (Stockholm, Sweden), A. Papi (Ferrara, Italy)
Late Breaking Abstract - Benralizumab treatment reduces the high-affinity IgE receptor on plasmacytoid dendritic cells in patients with severe asthma
G. Schwefel (Rostock, Germany), K. Bratke (Rostock, Germany), H. Marchewski (Rostock, Germany), J. Virchow (Rostock, Germany), M. Lommatzsch (Rostock, Germany)
|    |
Late Breaking Abstract - Matrix metalloproteinases in serum and sputum reflect distinct processes of relevance to asthma
A. James (Stockholm, Sweden), C. Gomez (Stockholm, Sweden), J. Thörngren (Stockholm, Sweden), M. Ericsson (Stockholm, Sweden), J. Kolmert (Stockholm, Sweden), C. Wheelock (Stockholm, Sweden), R. Knowles (Stevenage, United Kingdom), I. Adcock (London, United Kingdom), S. Dahlén (Stockholm, Sweden), .. U-Biopred & Bioair Study Groups (Stockholm, Sweden)
| |
Late Breaking Abstract - IgE-FceR1 cross-linking impairs the capacity of plasmacytoid dendritic cells to induce in vitro functional regulatory T cells which can be restored by Omalizumab
J. López-Abente (Madrid, Spain), C. Benito-Villalvilla (Madrid, Spain), X. Jaumont (Basel, Switzerland), P. Pfister (Basel, Switzerland), P. Tassinari (Basel, Switzerland), O. Palomares (Madrid, Spain)
| |
eNose breathprints as surrogate biomarkers for classifying asthma patients by atopy
M. Ibrahim (Amsterdam, Netherlands), P. Brinkman (Amsterdam, Netherlands), S. Vijverberg (Amsterdam, Netherlands), A. Neerincx (Amsterdam, Netherlands), S. Hashimoto (Amsterdam, Netherlands), R. De Vries (Amsterdam, Netherlands), Y. Dagelet (Amsterdam, Netherlands), K. Knipping (Utrecht, Netherlands), P. Sterk (Amsterdam, Netherlands), A. Kraneveld (Utrecht, Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands)
|  |
Baseline and longitudinal urinary eicosanoid profiles for molecular sub-phenotyping in the U-BIOPRED study
J. Kolmert (Stockholm, Sweden), C. Gómez (Stockholm, Sweden), D. Lefaudeux (Lyon, France), B. De Meulder (Lyon, France), I. Pandis (London, United Kingdom), R. Djukanovic (Southampton, United Kingdom), P. Sterk (Amsterdam, Netherlands), I. Adcook (London, United Kingdom), B. Dahlén (Stockholm, Sweden), S. Dahlén (Stockholm, Sweden), C. Wheelock (Stockholm, Sweden)
| |
Effect of house dust mite sublingual immunotherapy on airway inflammation and remodeling in allergic asthma with rhinitis
M. Hoshino (Atami, Japan), K. Akitsu (Atami, Japan), K. Kubota (Atami, Japan)
| |
Dupilumab Efficacy in Type 2 Inflammatory Asthma: Liberty Asthma QUEST Study
I. Pavord (Oxford, United Kingdom), J. Fitzgerald (Vancouver, Canada), G. Brusselle (Ghent, Belgium), S. Wenzel (Pittsburgh, United States of America), K. Rabe (Grosshandsdorf and Kiel, Germany), W. Busse (Madison, United States of America), A. Papi (Ferrara, Italy), M. Rice (Cambridge, United States of America), Y. Deniz (Tarrytown, United States of America), P. Rowe (Birdgewater, United States of America), N. Amin (Tarrytown, United States of America), N. Graham (Tarrytown, United States of America), A. Teper (Birdgewater, United States of America)
| |
Fevipiprant is superior to montelukast in suppressing type 2 cytokine production from mast cell stimulated human Th2 cells
S. Kazani (Cambridge, United States of America), F. Hasler (Basel, Switzerland), P. Jaeger (Basel, Switzerland), C. Maurer (Basel, Switzerland), D. Sandham (Cambridge, United States of America), T. Roehn (Basel, Switzerland)
| |